{"id":"NCT00628589","sponsor":"Alexza Pharmaceuticals, Inc.","briefTitle":"Staccato Loxapine in Agitated Patients With Schizophrenia","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of StaccatoÂ® Loxapine for Inhalation in Schizophrenic Patients With Agitation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2008-03-05","resultsPosted":"2017-06-29","lastUpdate":"2017-07-26"},"enrollment":344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Patients With Schizophrenia and Acute Agitation"],"interventions":[{"type":"DRUG","name":"Inhaled loxapine 5 mg","otherNames":["ADASUVE"]},{"type":"DRUG","name":"Inhaled loxapine 10 mg","otherNames":["ADASUVE"]},{"type":"DRUG","name":"Inhaled placebo","otherNames":[]}],"arms":[{"label":"Inhaled Loxapine 5 mg","type":"EXPERIMENTAL"},{"label":"Inhaled Loxapine 10 mg","type":"EXPERIMENTAL"},{"label":"Inhaled placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients","primaryOutcome":{"measure":"Change in PANSS-EC From Baseline","timeFrame":"Baseline and 2 hours","effectByArm":[{"arm":"Inhaled Placebo","deltaMin":-5.5,"sd":4.92},{"arm":"Inhaled Loxapine 5 mg","deltaMin":-8.1,"sd":5.17},{"arm":"Inhaled Loxapine 10 mg","deltaMin":-8.6,"sd":4.37}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0004"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21200077","29163985"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":115},"commonTop":["Sedation","Dizziness","Dysgeusia","Headache","Nausea"]}}